These findings highlight the potential of C. elegans not only as a model for understanding the genetic basis of GNAO1 encephalopathy but also as a platform for discovering novel therapeutic approaches, leading to several clinical trials (Table 1). This evidence concerns the gene GNAO1 and Encephalopathy.